

Contents

Chapter 1	Identification of Cellular Protein–Protein Interactions	1
	<i>Caroline Benz, Eszter Kassa, Elias Tjärnhage, Sara Bergström Lind and Ylva Ivarsson</i>	
1.1	Introduction	1
1.2	Mass Spectrometry-based Proteomics for Identification of PPIs	3
1.2.1	Affinity Purification Coupled to Mass Spectrometry (AP-MS)	5
1.2.2	Proximity-labeling MS: BioID and APEX	6
1.2.3	Crosslinking MS – XL-MS	8
1.3	Display Methods	9
1.3.1	Proteomic Peptide-phage Display – ProP-PD	10
1.3.2	mRNA Display	12
1.3.3	Yeast Surface Display	13
1.4	Array-based Methods	14
1.4.1	Protein Arrays	14
1.4.2	Peptide Arrays	16
1.5	Fluorescence- and Luminescence-based Methods	18
1.5.1	Förster Resonance Energy Transfer (FRET)	19
1.5.2	Bioluminescence Resonance Energy Transfer (BRET)	19
1.5.3	Luminescence-based Mammalian Interactome Mapping – LUMIER	20
1.6	Protein Complementation Assays (PCAs)	21
1.6.1	Split DHFR and Split TEV	21

Chemical Biology No. 17

Inhibitors of Protein–Protein Interactions

Edited by Ali Tavassoli

© The Royal Society of Chemistry 2021

Published by the Royal Society of Chemistry, www.rsc.org

1.6.2	Bimolecular Fluorescence Complementation (BiFC) and Bimolecular Luminescence Complementation (BiLC) Assays	23
1.7	Two-hybrid Methods	24
1.7.1	Yeast Two-hybrid (Y2H)	24
1.7.2	MYTH and MaMTH	26
1.7.3	Mammalian PPI Trap (MAPPIT)	27
1.8	Proximity Ligation Assay (PLA)	28
1.9	Concluding Remarks	29
	Acknowledgements	30
	References	30
Chapter 2	Target-based Screening and Structure-based Design Approaches to Develop Modulators of Protein–Protein Interactions	40
	<i>Ashley E. Modell and Paramjit S. Arora</i>	
2.1	The Challenge with Targeting Protein–Protein Interactions	40
2.2	Modulation of Protein–Protein Interactions	41
2.3	Classifying Protein–Protein Interactions	42
2.4	Overview of Approaches to Target Protein–Protein Interactions	45
2.5	Phenotypic Screening	45
2.5.1	Phenotypic Screening: Overview, Benefits, and Drawbacks	45
2.5.2	Phenotypic Screening Workflow	48
2.6	Target-based Approaches: Target-based Rational Design and Target-based Screening	48
2.6.1	Target-based Approaches: Overview, Benefits, and Drawbacks	48
2.6.2	Target-based: Rational Design Workflow	50
2.6.3	Target-based Screening Workflow	52
2.7	A Case Study: KIX/MLL	56
2.8	Conclusion and Outlook	58
	References	59
Chapter 3	The Challenge of Prosecuting Intracellular Protein–Protein Interactions: A Multi-modality Examination of Chemical Matter Identification, Biophysical Characterization, and Membrane Permeability	66
	<i>L. Fan, W. T. McElroy, T. K. Sawyer, P. R. Sheth and D. M. Tellers</i>	
3.1	Introduction	66

3.2	Biophysical Characterization of Protein–Ligand Interactions: An Essential Aspect of Discovery and Development	68
3.3	Small Molecules: The Preferred Entity for Drugging Intracellular PPIs	70
3.3.1	DNA-encoded Library Technology (DELTA)	70
3.3.2	Targeted Protein Degradation	76
3.4	Macrocyclic Peptides—Right Technology, Right Time?	82
3.4.1	Hit Identification and Application to Intracellular PPIs	82
3.4.2	Permeability as the Central Challenge	90
3.4.3	Strategies for Optimizing Ligandability and Permeability	93
3.4.4	Considerations Beyond Ligandability and Permeability	94
3.5	Antibody Approaches to Intracellular PPIs: Break on Through to the Other Side	95
3.5.1	Antibody Structural Modification to Achieve Cellular Permeability Properties	95
3.5.2	Antibody Cellular Delivery Using Varying Physical, Biological or Chemical Methods	96
3.5.3	Strategic Drug Development for Intracellularly Targeted Delivery of Antibodies	98
3.6	Outlook: The Challenge and Opportunity of Drugging Intracellular PPIs	99
	Acknowledgements	99
	References	99

Chapter 4 Identifying and Developing Small Molecule Inhibitors of Protein–Protein Interactions **111**

Rhian S. Holvey, Samuel E. Dalton, Tom D. Heightman and David C. Rees

4.1	Introduction	111
4.1.1	Drug Discovery in the Context of PPI Inhibitors	112
4.2	Venetoclax – A Selective Inhibitor of the BCL2 PPI Approved in Patients with Chronic Lymphocytic Leukaemia (CLL)	115
4.2.1	PPI Outline	115
4.2.2	Discovery of Navitoclax (5): A Non-selective BCL2/BCLX _L Inhibitor	125
4.2.3	The Problem of Platelets: Identifying a BCL2 Selective Inhibitor	127

4.3	ASTX660 – An Inhibitor of Cellular- and X-linked Inhibitor of Apoptosis Proteins in Phase I/II	127
4.3.1	PPI Outline	127
4.3.2	Discovery of Non-peptidomimetic Lead AT-IAP (14)	132
4.3.3	Optimisation to Clinical Candidate ASTX660	136
4.4	KI-696 (20): An Inhibitor of the KEAP1:NRF2 PPI	136
4.4.1	PPI Outline	136
4.4.2	Discovery and Development of Hits	138
4.4.3	Binding Affinity Optimisation with Conformational Control	139
4.5	Discovery of I-BET762 (22)	142
4.5.1	PPI Outline	142
4.5.2	Discovery of Initial Hits, and Deconvolution of Biological Targets	142
4.5.3	Optimisation of Hits to Afford I-BET762	145
4.6	Discovery of AZD5991 (R-29) – Inhibitor of MCL1-effector Protein Interactions	146
4.6.1	PPI Outline – Role of MCL1 in Cancer	146
4.6.2	Discovery and Development of Hits	146
4.6.3	Macrocyclisation and Optimisation	149
4.7	Conclusions and Outlook	150
	References	151
Chapter 5	Macrocycles as Inhibitors of Protein–Protein Interactions	160
	<i>Pierre-Luc Boudreault, Christian Comeau and Eric Marsault</i>	
5.1	Introduction	160
5.1.1	Macrocycles Are Privileged Structures for PPI Modulation	161
5.1.2	Finding the Sweet Spot in the bRo5 Space	162
5.2	Non-peptidic Macrocyclic Inhibitors of PPI	164
5.2.1	PPI Inhibitors with Potential in Immunology	165
5.2.2	PPI Inhibitors in Cancer	170
5.2.3	Conclusions	179
5.3	Peptidic and Semi-peptidic Inhibitors of PPI	179
5.3.1	Cancer	179
5.3.2	Infectious Diseases	196
5.3.3	Immunology and Inflammation	200
5.4	Conclusion	204
	References	205

Chapter 6	Genetically Encoded SICLOPPS Libraries for the Identification of PPI Inhibitors	218
	<i>Mikayla M. Fernholz, Leonie M. Windeln, Monika Papayova and Ali Tavassoli</i>	
6.1	Introduction	218
6.2	SICLOPPS	219
6.3	Library Construction	220
6.4	SICLOPPS Screening in Prokaryotes	222
6.5	SICLOPPS Screening in Eukaryotes	226
6.6	Moving Beyond Hits	228
	References	229
Chapter 7	RaPID Discovery of Macrocyclic Peptide Inhibitors of Protein–Protein Interactions	232
	<i>R. H. P. van Neer, A. A. Vinogradov and H. Suga</i>	
7.1	Disruption of the eVP24/KPNA5 PPI	234
7.2	Semaphorin–Plexin PPI Inhibition	237
7.3	HGF–MET PPI Inhibition	240
7.4	Conclusion	243
	Acknowledgements	243
	References	243
Chapter 8	Bicyclic Peptide Inhibitors of Protein–Protein Interactions	247
	<i>Marina Buyanova and Dehua Pei</i>	
8.1	Introduction	247
8.2	Source of Bicyclic Peptides	248
8.2.1	Bicyclic Peptides from Nature	248
8.2.2	Bicyclic Peptides by Phage Display	249
8.2.3	Bicyclic Lanthipeptide Libraries	250
8.2.4	Bicyclic Peptides by SICLOPPS	252
8.2.5	Bicyclic Peptides by mRNA Display	252
8.2.6	Bicyclic Peptides from OBTC Libraries	254
8.3	Bicyclic Peptidyl Inhibitors against Extracellular PPIs	255
8.3.1	TNF α	255
8.3.2	Epidermal Growth Factor	257
8.3.3	Notch Receptors	257
8.3.4	HER2	257
8.3.5	Integrin Receptors	259
8.3.6	G-protein Coupled Receptors	259

8.3.7	Neuropilin Receptors	261
8.3.8	Enzyme–Substrate Interactions	261
8.4	Bicyclic Peptidyl Inhibitors against Intracellular PPIs	264
8.4.1	Enzyme–Substrate Interactions	265
8.4.2	Small GTPases	267
8.4.3	NEMO–IKK Interaction	269
8.4.4	Bcl2 Family Proteins	271
8.4.5	SH2 Domains	271
8.4.6	c-Myc	272
8.4.7	HECT Domain Ligases	274
8.4.8	p6–UEV Interaction	274
8.5	Conclusion and Future Directions	274
	Acknowledgements	275
	References	275
Chapter 9	Stapled Peptide Inhibitors of Protein–Protein Interactions	280
	<i>Mathias Wendt, Niall M. McLoughlin and Tom N. Grossmann</i>	
9.1	Introduction	280
9.2	One-component Peptide Stapling	284
9.3	Two-component Peptide Stapling	289
9.4	Stapled Peptides Targeting MDM2/MDMX	292
9.5	Conclusion	297
	Acknowledgements	297
	References	297
Chapter 10	α-Helix Mimetics as Inhibitors of Protein–Protein Interactions	305
	<i>A. J. Wilson</i>	
10.1	Introduction	305
10.1.1	The α -Helix as a Generic Recognition Motif	307
10.1.2	Exemplar α -Helix Mediated PPIs	308
10.2	Topological Mimics of the α -Helix	310
10.2.1	β -Peptides as Inhibitors of α -Helix Mediated PPIs	311
10.2.2	Mixed α/β -Foldamers as PPI Inhibitors	311
10.2.3	Mixed $\alpha/\beta/\gamma$ -Peptides as Faithful Topological Mimics of the α -Helix	312
10.2.4	Other Foldamers as α -Helix Mimetics	313

<i>Contents</i>	xiii
10.3 Topographical Mimics of the α -Helix	315
10.3.1 Terphenyls and Their Variants as α -Helix Mimetics	315
10.3.2 Aromatic Oligoamides as α -Helix Mimetics	317
10.3.3 Oligooxopiperazines as α -Helix Mimetics	324
10.3.4 Other Classes of α -Helix Mimetics	325
10.4 Conclusions	328
Acknowledgements	328
References	329
Subject Index	336

